LOC-R01 trial stays active-not-recruiting in study of lenalidomide and ibrutinib with R-MPV — LiveFuture News
Open on LiveFuture.ai →

LOC-R01 trial stays active-not-recruiting in study of lenalidomide and ibrutinib with R-MPV

ClinicalTrials.gov lists LOC-R01 as active not recruiting, with randomized arms testing R-MPV plus lenalidomide or ibrutinib and no posted results yet.

LOC-R01 is listed on ClinicalTrials.gov as ACTIVE_NOT_RECRUITING, which means the study is no longer taking new participants but is still being followed. The registry entry was published 2026-10-19T00:00:00+00:00, and there are no posted results yet, so the public can see the design but not the outcome.

For readers, the key point is simple: this is a randomized cancer study comparing two treatment arms built around R-MPV, a regimen named in the record as Rituximab-Methotrexate Procarbazine Vincristin. One arm pairs R-MPV with Lenalidomide, and the other pairs R-MPV with Ibrutinib.

"This record describes a study and its registry status; study outcomes require posted results."

The sponsor named in the entry is Institut Curie. The trial is identified as PHASE1, PHASE2, and the registry lists a randomized allocation with two active-comparator arms, which means each group is receiving an active treatment rather than an inactive placeholder.

The study title is the LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV). The intervention list names Lenalidomide for Arm A and Ibrutinib for Arm B, keeping the comparison focused on which added drug is paired with the same base regimen.

"The phase Ib is a 3+3 dose escalation design"

The first listed primary outcome is Dose Limiting Toxicity during the first cycle of treatment for each treatment arm, with a time frame of 1 month. That tells readers the early part of the study is watching closely for side effects that may limit dosing.

The phase II primary endpoint is Complete Response rate including unconfirmed Complete Response at the end of the 4 cycles of induction therapy, with a time frame of 4 months. The record says response assessment will be based on the International Primary Central Nervous System Lymphoma Collaborative Group (IPCG), which gives the study a structured way to judge response.

"The primary endpoint for the phase II part of the study is the Complete Response (CR) rate including unconfirmed CR (CR+uCR) at the end of the 4 cycles of induction therapy."

The registry also gives a far-off estimated primary completion date of 2035-02-02. That makes the study look long-running, but the only firm present-tense fact is its current registry status, not any medical result.

Anyone tracking cancer research can place LOC-R01 within the broader Cancer Breakthroughs special event, but the entry itself should be read narrowly: it is a live study record, not a claim of success. For more context on this ongoing event, see Cancer Breakthroughs.